Assessing Mn as an antioxidant agent in bioactive glasses by quantification of catalase and superoxide dismutase enzymatic mimetic activities

The antioxidant activity of Mn as additive in a 45S5 type glass system with and without P2O5 was studied by mimicking the activity of catalase (CMA) and superoxide dismutase (SOD) enzymes. Glasses were melted either under oxidizing or reducing atmosphere (N2/H2) to compare the processing influence on the Mn oxidation state. Thermal (DTA) and optical (UV–Vis) characterizations of the glass powders were carried out to obtain further insight into the structural role of Mn. A correlation of in vitro apatite formation between Tris buffer solution and Simulated Body Fluid (SBF) was performed to optimise Mn substitution, where a decrease in apatite formation was observed by increasing Mn content. Despite this, glasses with up to 1.0 mol% MnO did not show any delay in apatite formation and maintained their CMA and SOD activity. The antioxidant effect of Mn can be attributed to the interconversion Mn2+ ↔ Mn3+ occurring on the glass surface through a heterogeneous catalysis. P2O5 plays an important role in the antioxidant effect of the glass, possibly by charge balancing Mn ions and forming more stable units compared to those formed with Ca and Na. The amount of Mn2+ is predominant in the glass network with respect to Mn3+ in all synthetized glasses. Moreover, glass melting in a reducing atmosphere further avoided Mn oxidation

Multi-messenger observations of a binary neutron star merger

On 2017 August 17 a binary neutron star coalescence candidate (later designated GW170817) with merger time 12:41:04 UTC was observed through gravitational waves by the Advanced LIGO and Advanced Virgo detectors. The Fermi Gamma-ray Burst Monitor independently detected a gamma-ray burst (GRB 170817A) with a time delay of ~1.7 s with respect to the merger time. From the gravitational-wave signal, the source was initially localized to a sky region of 31 deg2 at a luminosity distance of 40+8-8 Mpc and with component masses consistent with neutron stars. The component masses were later measured to be in the range 0.86 to 2.26 Mo. An extensive observing campaign was launched across the electromagnetic spectrum leading to the discovery of a bright optical transient (SSS17a, now with the IAU identification of AT 2017gfo) in NGC 4993 (at ~40 Mpc) less than 11 hours after the merger by the One- Meter, Two Hemisphere (1M2H) team using the 1 m Swope Telescope. The optical transient was independently detected by multiple teams within an hour. Subsequent observations targeted the object and its environment. Early ultraviolet observations revealed a blue transient that faded within 48 hours. Optical and infrared observations showed a redward evolution over ~10 days. Following early non-detections, X-ray and radio emission were discovered at the transient’s position ~9 and ~16 days, respectively, after the merger. Both the X-ray and radio emission likely arise from a physical process that is distinct from the one that generates the UV/optical/near-infrared emission. No ultra-high-energy gamma-rays and no neutrino candidates consistent with the source were found in follow-up searches. These observations support the hypothesis that GW170817 was produced by the merger of two neutron stars in NGC4993 followed by a short gamma-ray burst (GRB 170817A) and a kilonova/macronova powered by the radioactive decay of r-process nuclei synthesized in the ejecta

Comparison of microstructure, sintering behavior, and biological response of sol-gel and melt-derived 13–93 bioactive glass scaffolds

In this study, 13–93 bioactive glass (BG) powders were obtained through the traditional melt-quenching and sol-gel approaches and were used to fabricate scaffolds using the well-known foam replica technique. A comparative analysis of scaffolds prepared using sol-gel and melt-derived powders was carried out. The microstructure of scaffolds was examined by scanning electron microscopy (SEM) and X-ray computed tomography. The shrinkage behavior of the scaffold structure during sintering was investigated using heating microscopy (HM). The bioactivity results indicated the formation of a hydroxyapatite layer on the surface of both scaffolds after immersion in simulated body fluid (SBF) for 7 days. In vitro cell viability results revealed that both scaffolds are cytocompatible with MG-63 cells (osteoblast-like cell line). The findings indicate that sol-gel glass-derived 13–93 scaffolds exhibited similar characteristics to the well-known melt-derived 13–93 scaffolds. Moreover, the low-temperature processing and high purity associated with the sol-gel approach suggest that sol-gel derived 13–93 BG powder is attractive for fabricating high-quality scaffolds

Effects of linear and undulating periodization of strength training in the acceleration of skater children

Abstract Aim: This study aimed to compare the effects of linear periodization (LP) and undulating periodization (UP) of strength training on acceleration in skater children. Methods: Twenty-nine girls (9.67±1.29 years-old, 34.47±8.06kg, 1.39±0.13m) were distributed into two groups: linear periodization group (LPG, n=14) and undulating periodization group (UPG, n=15). Six levels of progressive training were designed based on activities such as multi-jumps, plyometrics, sled towing, and facilitated exercises. The training lasted 16 weeks, with a 1-h session on three non-consecutive days per week. The acceleration was recorded by digital videography following the major trochanter of the femur, at four moments and under two conditions: static (SS) and dynamic start (DS) in a rectilinear path. Statistical significance was set at 5%. Results: ANOVA indicated group*moment interaction in SS and DS for velocity (F3,81=7.883; p<0.001; pη2=0.226; F3,81=2.36; p=0.078; pη2=0.08-trend, respectively) and acceleration (F3,81=3.96; p=0.011; pη2=0.128; F3,81=2.92; p=0.039; pη2=0.098, respectively). Both groups increased velocity in SS and DS (UPG/SS: 1st=4.07, 2nd=9.75, 3rd=8.91, 4th=9.25m/s; LPG/SS: 1st=4.27, 2nd=7.13, 3rd=7.61, 4th=7.99m/s; UPG/DS: 1st=8.30, 2nd=8.73, 3rd=8.12, 4th=9.27m/s; LPG/DS: 1st=8.20, 2nd=8.31, 3rd=7.90, 4th=8.96m/s) and acceleration (UPG/SS: 1st=2.00, 2nd=8.69, 3rd=4.71, 4th=5.02m/s2; LPG/SS: 1st=2.37, 2nd=3.39, 3rd=3.68, 4th=4.12m/s2; UPG/DS: 1st=1.78, 2nd=1.97, 3rd=1.65, 4th=2.46m/s2; LPG/DS: 1st=1.67, 2nd=1.70, 3rd=1.48, 4th=1.93m/s2). Conclusion: Both strength training periodization protocols were effective in developing acceleration and velocity in girl skaters over 16 weeks; however, UP was more efficient than LP for improving acceleration

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events